Qilin Zhang1,2,3, Ziyan Xu1, Rui Han1,2

  • 1Center for Cell and Gene Therapy, Clinical Research Center for Cell-based Immunotherapy, Shanghai Pudong Hospital, Institutes of Biomedical Sciences, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200433, China.

Nature communications
|September 27, 2024
PubMed
概括

这项研究揭示了染色体的不稳定性是基冠状瘤的关键因素,影响治疗结果和患者的预后. 研究结果强调了RPRD1B和免疫逃避作为这种攻击性骨癌的潜在治疗点.